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Abstract
A series of synthetic molecules combining a geranyl backbone with a heterocyclic or oxime head group are quorum-sensing molecules that
block the yeast to mycelium transition in the dimorphic fungus Candida albicans. A number of the analogs have an IC50 ≤ 10 μM, a level of potency essentially identical to the natural quorum sensing signal, the sesquiterpene farnesol. Two of the most potent analogs, neither toxic toward
healthy mice, display remarkably different effects when co-administered with C. albicans. While neither offers protection from candidiasis, one
analog mimics farnesol in acting as a virulence factor, whereas the other has no effect. The results offer the first example of highly potent synthetic fungal quorum-sensing molecules, and provide the first evidence for the ability to decouple quorum sensing and virulence.
Graphical abstract
A series of farnesol analogs are potent quorum-sensing molecules for the human pathogen Candida albicans. Two of the most potent analogs
display very different effects in a mammalian model of systemic candidiasis.
Keywords: Farnesol, Quorum sensing, Candida albicans, Virulence, Candidiasis, Oxime, Tetrazole, Triazole, Thiotetrazole, Thiotriazole,
Thioimidazole

1. Introduction
Candida albicans normally resides as a harmless yeast in the
GI and urinary tracts, and to a lesser extent on the skin, of
most humans. However, for patients with weakened immune
systems (e.g., AIDS patients, transplant recipients, and premature infants) C. albicans is an opportunistic and often deadly
pathogen that will invade host tissues, undergo a dimorphic
shift, and then grow as a fungal mass in the kidney, heart, or
brain. Candida albicans is the fourth leading cause of hospital-acquired infection in the United States and over 95% of
AIDS patients will suffer from infections by C. albicans.[1]
and [2] There is a pressing need for new treatments for fungal
infections.
Candida albicans is a polymorphic fungus able to grow as
yeasts, hyphae, and pseudohyphae, and a great many chemical
and environmental factors influence the relative populations of
these morphologies. In liquid culture, C. albicans develops as
either yeasts or hyphae, depending in part on whether the cell
densities are above or below 106 cells per ml.3 Our research
revealed that the population dependence of C. albicans morphology results from the continuous production and detection

of the sesquiterpene farnesol (1, Table 1),[3] and [4] which acts
to block the yeast to mycelium transition at concentrations as
low as 1–2 μM.[5] and [6] In accordance with the precedent established for homoserine lactones in Gram-negative bacteria,7
the phenomenon was termed quorum sensing. Farnesol was
the first quorum-sensing molecule (QSM) to be discovered in
an eukaryotic system.[3] and [4]
The dimorphic nature of C. albicans is essential for pathogenicity.8 The discovery of a QSM able to direct growth in
the yeast phase therefore suggested the possibility of a “single morphology therapy” which would force this opportunistic pathogen to remain in a monomorphic, nonpathogenic lifestyle. However, three separate experiments have shown that
farnesol actually increases fungal pathogenicity. First, cultures
of C. albicans pretreated with subinhibitory doses of fluconazole, a protocol that increases the levels of secreted farnesol
8- to 10-fold,9 were 4- to 5-fold more pathogenic to mice.10
Second, mice which received farnesol either in their drinking
water or via intraperitoneal injection showed ca. 4-fold higher
lethality from candidiasis than mice receiving control IP injections.11 Third, a knockout mutant of C. albicans lacking the
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Table 1. QSM activity of oximes

2.1. Oxime leads for new QSMs
While developing a series of fluorescent farnesol analogs,13 we discovered a pentaene oxime 2 with QSM activity (IC50 = 10 μM) superior to any previously investigated
analog (Table 1; see the experimental section for a description of the QSM assay). Based on this discovery, we prepared the oxime of farnesaldehyde (3) and found it was also
a potent QSM (IC50 = 5 μM, Table 1). The corresponding Omethyl ether, farnesaldehyde methoxyoxime 4, was inactive
(IC50 > 100 μM), consistent with the results of earlier studies pointing to a requirement for an acidic head group.6 However, oxime 3 was found to exhibit significant toxicity (IP)
in healthy mice and this class of molecules was not pursued
further.

a Inhibition

of germ tube formation.
Healthy mice observed over 14 d following injection (IP) with 1 ml of 20
mM solution (0.5% Tween 80 v/v in sterile, nonpyrogenic saline).
c Not determined.
d Mice died within 4–5 days.
b

DPP3 gene encoding an isoprenoid pyrophosphatase for conversion of farnesyl pyrophosphate to farnesol, and thus producing only 15% as much farnesol as the wild-type, was 4- to
5-fold less pathogenic. Reconstitution of DPP3 restored both
farnesol production and pathogenicity.11 Taken together, these
observations show that farnesol can act as a virulence factor
for C. albicans. We have subsequently discovered a potential
basis for this behavior, in that farnesol interferes with the normal progression of cytokine induction in mice infected with
C. albicans.12
We are interested in the relationships between quorum
sensing and virulence and, in particular, whether it is possible to decouple the two. Specifically, we were interested in the
possibility of designing analogs that retain farnesol’s ability
to block hyphal development but lack farnesol’s activity as a
virulence factor. In order to explore this problem, we required
potent QSMs structurally distinct from farnesol. We now report the discovery of a series of highly potent synthetic quorum-sensing molecules, as well as preliminary investigations
of their activity in a mouse model of systemic candidiasis.

2.2. Tetrazole QSMs
The high quorum-sensing activity of oximes 2 and 3 led us
to explore replacement of the primary alcohol of farnesol with other acidic functional groups (Fig. 1). Our earlier
work had found farnesoic acid to be a weakly active QSM
(IC50 = 36 μM).6 5-Substituted-1H-tetrazoles are weak acids
(pK ~ 5) often used as lipophilic isosteres for carboxylic acids,[14] and [15] and therefore we investigated several analogs incorporating a tetrazole in place of C1–C3 of farnesol.
Analogs 5, 6, and 7 were synthesized via cycloaddition of
the appropriate nitrile with Et3NHN3, generated in situ from
NaN3 (Scheme 1).16
Analog 5, which incorporates a tetrazole in place of the
C1–C3 region of farnesol, was a potent QSM with IC50 = 7 μM
(Table 2). However, in agreement with conclusions from our
earlier research,6 chain length was clearly important. Tetrazole
6, although possessing only one fewer backbone carbon than 5,
was considerably less active, while commercially available 5methyl-1-tetrazole (not shown) was inactive as a QSM at concentrations up to 3 mM. Nonyl tetrazole 7 and commercially

2. Results
When we initiated these studies, there were no synthetic molecules possessing a significant fraction of farnesol’s biological activity as a quorum-sensing molecule. Previously, we had
probed farnesol’s mode of action with over 40 natural and synthetic farnesol analogs.6 Modified structural features included
the head group, chain length, presence or absence of the
three double bonds, substitution of a backbone carbon by S,
O, N, and Se heteroatoms, presence or absence of a 3-methyl
branch, and bulkiness of the hydrophobic tail. Although, more
than half the compounds showed measurable quorum-sensing
activity (inhibition of hyphal development), the best displayed
only 7% of the activity of E,E-farnesol.6

Figure 1. Design concept for analogs.

Scheme 1. Synthesis of Tetrazoles.
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available styrenyl tetrazole 8 were also highly active; however, 7 was only marginally soluble in water. The strong quorum-sensing activity observed for analogs 5 and 8 implies a
functional equivalency between styrene and 4,8-dimethyl-3,7nonadiene sidechains, suggesting that 3-methyl-5-phenyl-2,4pentadienol or similar structures might represent productive
future targets as synthetic QSMs.17 Along these lines, it is interesting to note a report indicating that dodecanol, an analog
of the 12-carbon homoserine lactone secreted as a QSM by
Pseudomonas aeruginosa, is a weak QSM for C. albicans.18
2.3. Other heterocyclic QSMs
The potency of the tetrazoles as quorum-sensing molecules
led us to investigate additional examples of five-membered
heterocyclic analogs possessing the same approximate shape,
crosssection, lipophilicity, and molecular length (Scheme 2).
Our previous studies had found the replacement of a methylene with a sulfur atom (thioether) to be a well-tolerated
structural modification,6 and we therefore mainly focused on
sulfur-linked heterocycles, which are readily available via nucleophilic displacement (Scheme 2).19 A similar approach has
been employed for synthesis of a thiotriazole from farnesyl
chloride.20 The substrates tested grafted a series of heterocyclic head groups onto a geranyl (3,7-dimethyl-2,6-octadienyl)
tail: thio-1,2,3,4-tetrazole (9), thio-1,2,4-triazole (10), thio1,2,3-triazole (11), and thioimidazole (12). We also investigated a carbon-linked 1,2,3-triazole (13) prepared through a
dipolar cycloaddition (Eq. 1).21
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tonitis and mild hepatomegaly in some mice. Therefore, analogs 5 and 10 were chosen for further testing with a standard
mouse model of candidiasis,[10] and [11] employing tail vein injection of C. albicans cells and IP injection of the analogs.
Forty-five mice were inoculated with 5 × 106 cells of C. albicans A72 through tail vein injection; an additional 45 mice
were inoculated with 2 × 106 cells. Each batch of mice was divided into 3 groups of 15 mice each. The chosen doses provide ca. 50% mortality after 3 days with strain C. albicans
A72;10 virtually identical results were obtained with each
dose. Group 1 was given a control injection (IP, 1 ml of 0.5%
Tween 80 in saline) while groups 2 and 3 were injected with
Table 2. Quorum sensing and toxicity of tetrazoles

a,b See

Table 1.

(1)
Although thiotetrazole 9 and thioimidazole 12 were only
minimally active (IC50 > 50 μM), triazoles 10, 11, and 13
were potent QSMs (Table 3). It is notable that two of the analogs (10 and 13) exhibit QSM activity equal to E,E-farnesol,
with three other analogs (5, 7, and 11) displaying activities
nearly as great. It is important to note that none of the compounds listed in Table 1 and Table 2 had any inhibitory effects
on the rate of cell growth, even at the highest concentrations
tested (≥100 μm).

Scheme 2. Additional heterocyclic analogs.

Table 3. Quorum sensing and toxicity in 9–13

2.4. Effect of heterocyclic QSMs on candidiasis
In selecting analogs for mouse assays, we eliminated the
nonyl tetrazole 7 due to limited water solubility. Three of the
most potent synthetic QSMs (5, 10, and 11) were tested next
for their potential toxicity to mice following IP injection of
1 ml of a 20 mM solution (ca. 4.4 mg of analog in 0.5% v/
v Tween 80 in sterile, nonpyrogenic saline). Attempts to use
0.1% Triton X-100 in place of Tween 80 were precluded by
toxicity. In an initial experiment with 3 mice per group, no
toxicity was observed for at least 14 days following injection.
In a follow-up experiment with 15 mice per group, also observed for at least 14 days, injection of 11 caused a slight peri-

a,b See

Table 1; c R = geranyl.

 

Figure 2. Influence of 5 and 10 on systemic candidiasis. Mouse mortality in
the presence and absence of tetrazole 5 and triazole 10 following inoculation
with C. albicans A72 (5 × 106 cells) and IP injection of 1 ml of: • (saline); ▲
(20 mM thio-1,2,4-triazole 10 in 0.5% Tween 80); ■ (20 mM tetrazole 5 in
0.5% Tween 80).

analogs 5 and 10, respectively. Neither analog protected the
mice from candidiasis (Fig. 2). In the case of the thiotriazole
10, mouse lethality closely paralleled that observed for the
control Tween 80 injections. In contrast, coadministration of
tetrazole 5 enhanced the pathogenicity of C. albicans A72 ca.
4- to 5-fold, almost exactly duplicating the effects of farnesol.[10] and [11] The effect is sufficiently pronounced that the entire group of 15 mice treated with 5 died within 60 h of infection. It is noteworthy that 5 and 10 display opposing effects
in vitro (QSM) and in vivo (pathogenicity). Thiotriazole 10
is ca. 7-fold more potent than 5 as a QSM but, unlike the tetrazole, it does not act as a farnesol-mimic in promoting virulence. Thus, the two analogs uncouple the in vitro and in vivo
effects of farnesol.
3. Discussion
Farnesol is a biologically active, lipid-soluble molecule. We
have shown that it blocks the yeast to mycelium transition in
C. albicans,3 acts as a virulence factor in a mouse model of
systemic candidiasis,[10] and [11] probably by interfering with
the normal progression of cytokine expression in their immune
response,12 and triggers apoptosis in the fungus Aspergillus
nidulans.22 Others have shown that farnesol alters circadian
rhythms in Neurospora crassa and targets HMG CoA reductase for proteolysis in both Saccharomyces cerevisiae and
Chinese hamster ovary cells.[23], [24] and [25] Farnesol has also
been shown to block calcium channels, stimulating cell differentiation, and triggering apoptosis in other mammalian cell
lines.26 Farnesol-induced apoptosis has also been reported in
tobacco cells.27 In addition, farnesol has recently been found
to be a potent and selective inhibitor of one class of monoamine oxidases (MAO-B).28 The family of heterocyclic farnesol analogs described above now provides a tool to discriminate between yeast-hyphal quorum sensing and pathogenicity.
In particular, the availability of molecules such as tetrazole 5
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(a potent quorum-sensing molecule which enhances pathogenicity) and 10 (a potent quorum-sensing molecule which does
not enhance pathogenicity) may provide a potent tool in understanding how farnesol functions as a virulence factor in interactions with cellular macrophages and CD4 T cells to alter
adaptive immunity.12 The analogs also provide a means of establishing differences and similarities between farnesol’s effect on virulence and its ability to block both hyphal development and biofilm formation.[3] and [29] Along these lines, it
is interesting to note that an analog of triazole 10 bearing five
additional carbons has been reported to be a potent activator
of protein kinase C.20 Of course, the differences in the pathogenicity of C. albicans observed in the presence of farnesol,
5, and 10 could also be due to differing pharmacokinetics or
their differing influence on mouse cytokine production.
It is also intriguing to consider the basis for the failure of
farnesol, tetrazole 5, or thiotriazole 10 to exert any protective
role on the course of systemic candidiasis. One possibility is
that the conditions of the experiment were not well suited to
test the potential of quorum-sensing molecules as fungistatic
therapeutics. Mycelia, the invasive form of the fungi capable
of penetrating host tissues to enter the bloodstream, are disfavored by the addition of exogenous farnesol or synthetic
QSMs. However, the standard experimental protocol calls
for injection of C. albicans directly into the bloodstream (tail
vein), potentially minimizing the influence of any regimen
that disfavors the mycelial morphology. Three other clinical
models of candidiasis, oral,30 vaginal,31 and gastrointestinal,32
may provide a more relevant test of the potential of a ‘single
morphology’ therapy for control of fungal infections.
4. Conclusion
We have discovered a family of synthetic quorum-sensing
molecules for C. albicans possessing in vitro potency comparable to E,E-farnesol, the natural signal. Investigations of
several of the analogs in a mouse model reveals no protection
against systemic candidiasis, but do demonstrate the ability to
decouple quorum sensing and virulence, suggesting this family of farnesol analogs may prove extremely useful in dissecting the basis for farnesol’s many biological activities.
5. Experimental
5.1. General procedures
Tetrahydrofuran (THF) was distilled from sodium/benzophenone. Other solvents were used as received. All reactions
were performed under N2 in oven-dried or flame-dried glassware. All new compounds were characterized by 1H, 13C, IR,
and HRMS. NMR spectra were recorded at 400 MHz (1H) or
100 MHz (13C) in CDCl3 unless otherwise noted. IR spectra were collected on NaCl plates. Melting points are uncorrected. Mass spectra were acquired at the Nebraska Center for
Mass Spectrometry (Lincoln, NE). TLC analyses were conducted on Analtech 0.25 mm GHLF plates, with analytes vi-
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sualized by UV, by dipping in 1% KMnO4 (specific for alkenes), or by charring after exposure to an aqueous solution
of ceric sulfate and ammonium molybdate (general indicator). (E)-5-(2-phenylethyenyl)-1H-tetrazole (8) was purchased
from Alfa Aesar (“listed as 5-styryl-1H-1,2,3,4-tetrazole”) and
used without purification. Abbreviations: EA, ethyl acetate;
hex; hexane; HOAc, acetic acid; NBA, 3-nitrobenzylalcohol.
5.2. Assay of quorum sensing
Assays for quorum sensing,3 toxicity to mice,[10] and [11] and
mortality have been described;[10] and [11] a brief overview follows: undifferentiated cells are inoculated to a final density
of 1–2 × 107 cells/ml into a solution of N-acetyl glucosamine
(2.5 mM, buffered to pH 7) and incubated for 4 h while shaking (200 rpm, 37 °C), after which the relative percentage of
cells with germ tube formation (GTF) is determined. Values
from triplicate readings are always within 10% of the mean
value. The relative percentage of cells displaying GTF, 95–
98% for cells grown on unsupplemented media, is reduced
considerably in the presence of farnesol or related QSMs.5
5.3. Preparation of Substrates
The preparation of oximes 2 (anti, 2E,4E,6E,8E)-3,7,11-trimethyldodeca-2,4,6,8,10-pentaenal oxime)13 and 3 (anti,
2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienal oxime)33 has
been described.
5.3.1. anti- and syn-(2E,6E)-3,7,11-Trimethyldodeca-2,6,10trienal,O-methyl oxime [anti-4 and syn-4]
Into a pyridine solution (5 ml) of methoxylamine hydrochloride (0.109 g, 1.3 mmol) was added (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienal (0.115 g, 0.52 mmol; available
through oxidation of commercially available farnesol with
MnO2 or chromic acid). After 4 h the reaction mixture was diluted with water (50 ml) and extracted with 30% Et2O/Hex
(100 ml). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to afford a mixture which
was separated by flash chromatography (2% Et2O/Hex) to afford a mixture of anti-4 (0.080 g, 62%) and syn-4 (0.045 g,
38%).
anti-4. Rf = 0.3 (5% EA/Hex); 1H δ 8.01 (d, 1H, J = 10.4),
5.92 (d, 1H, J = 9.6), 5.09 (m, 2H), 3.86 (s, 3H), 2.15 (m, 4H),
2.05 (m, 2h), 1.97 (m, 2H), 1.82 (d, 3H, J = 1.2), 1.68 (s, 3H),
1.60 (s, 6H); 13C δ 147.7, 147.5, 135.8, 131.3, 124.2, 123.2,
117.8, 61.5, 40.0, 39.6, 26.7, 26.0, 25.7, 17.7, 17.2, 16.0; IR
2965, 2932, 2855, 1443, 1051; MS (HR FAB, 3-NBA) calcd
for C16H28NO (MH+): 250.2171; found 250.2160 (4.4 ppm).
syn-4. Rf = 0.2 (5% EA/Hex) 1H δ 7.27 (d, 1H, J = 10),
6.41 (dd, 1H, J = 10, 1.2), 5.09 (m, 2H), 3.90 (s, 3H), 2.17 (m,
4H), 2.06 (m, 2H), 1.98 (m, 2H), 1.87 (d, 3H, J = 1.2), 1.69
(d, 3H, J = 0.8), 1.61 (s, 6H); 13C δ 149.8, 144.8, 135.9, 131.4,
124.2, 123.2, 113.3, 61.8, 40.2, 39.7, 26.7, 26.1, 25.7, 17.7,
17.1, 16.0; IR 2964, 2932, 2855, 1639, 1441, 1056; MS (HR
FAB, 3-NBA) calcd for C16H28NO (MH+): 250.2171; found
250.2166 (1.8 ppm).
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5.3.2. (E)-5,9-Dimethyldeca-4,8-dienenitrile
This compound was prepared by a variant of a known
procedure.34 Into a −78 °C solution of acetonitrile (0.52 ml,
10 mmol) in dry THF (10 ml) was added dropwise n-BuLi
(5 mmol, 2.0 ml, nominally 2.5 M in hexane), followed by
geranyl chloride (0.37 ml, 2.0 mmol). The reaction was allowed to warm to rt, and, after 30 min, quenched with water.
The mixture was extracted with 10% EA/hex (150 ml) and the
organic layer was dried over Na2SO4. The crude residue obtained upon concentration was purified by flash chromatography (5% EA/Hex) to afford 0.28 g (79%) of the nitrile as a
colorless oil: Rf = 0.2 (5% EA/Hex).
5.3.3. (E)-5-(4,8-Dimethylnona-3,7-dienyl)-1H-tetrazole (5)
Into a suspension of NaN3 (0.455 g, 7.00 mmol) in toluene (5 ml) was added Et3NHCl (Fluka, 1.10 g, 8.00 mmol) followed by a solution of (E)-5,9-dimethyldeca-4,8-dienenitrile
(see above, 2.00 mmol, 0.354 g) in 2 ml of toluene. The reaction mixture was held at reflux for 24 h and then allowed to cool
to rt. The mixture was acidified to pH 1 with 10% aq HCl
and extracted with 20% EA/Hex (3× 100 ml). The combined
organic layers were concentrated under reduced pressure and
the residue purified by flash chromatography (Hex/EA/AcOH
10:2:1) to furnish 0.41 g (93%) of tetrazole 5 as a colorless oil:
Rf = 0.3 (5:1:1, Hex/AcOH/EA); 1H δ 13.55 (br s, 1H), 5.18
(t, 1H, J = 6.8), 5.04 (t, 1H, J = 6.5), 3.14 (t, 2H, J = 7.6), 2.56
(q, 2H, J = 7.2), 2.03 (m, 2H), 1.97 (m, 2H), 1.66 (s, 3H), 1.66
(s, 3H), 1.58 (s, 3H), 1.52 (s, 3H); 13C δ 156.5, 138.4, 132.0,
124.0, 121.3, 39.5, 26.4, 26.1, 25.6, 23.7, 17.7, 15.9; IR 2917,
2625, 1558, 1441, 1376, 1253; HR-FABMS (3-NBA) calcd for
C12H21N4 (MH+): 221.1766; found: 221.1771 (2.1 ppm).
5.3.4. (E)-4,8-Dimethylnona-3,7-dienenitrile35
Into a solution of NaCN (0.196 g, 4.00 mmol) in ethanol
(10 ml) was added geranyl chloride (0.37 ml, 2.0 mmol). The
reaction mixture was stirred for 2 h, diluted with water, and
with 5% EA/Hex (twice). The separated organic layer was
dried over Na2SO4 and concentrated in vacuo. The residue was
purified by column chromatography (5% EA/Hex) to furnish
0.313 g (96%) of the known nitrile: Rf = 0.3 (5% EA/Hex).
5.3.5. (E)-5-(3,7-Dimethylocta-2,6-dienyl)-1H-tetrazole (6)
This compound was prepared from (E)-5-(3,7-dimethylocta-2,6-dienenitrile (0.31 g, 1.9 mmol) by a similar approach
as for 5. The product (0.37 g, 95%) was a colorless crystal
(mp = 52–54 °C, uncorrected) used without further purification: Rf = 0.3 (5:1:1, Hex/AcOH/EA); 1H δ 12.8 (br s, 1H), 5.45
(dt, 1H, J = 7.2, 1.2), 5.05 (m, 1H), 3.82 (d, 2H, J = 7.6), 2.05
(m, 4H), 1.69 (s, 3H), 1.68 (s, 3H), 1.57(s, 3H); 13C δ 156.0,
141.5, 132.2, 123.9, 115.7, 39.3, 26.2, 25.6, 22.5, 17.6, 16.2; IR
3417, 2971, 2916, 2732, 2253; HR-FABMS (3-NBA) calcd for
C11H19N4 (MH+): 207.1610; found: 207.1612 (1.3 ppm).
5.3.6. 5-Nonyl-1H-tetrazole (7)
This compound was prepared from decanonitrile (0.38 ml,
2.0 mmol) by a similar method as employed for synthesis of

S hchepin

5 and 6. The crude material (0.359 g, 91%) displayed spectra
identical to literature reports36 and was used without further
purification: Rf = 0.2 (5:1:1, Hex/AcOH/EA).

5.3.10. (E)-2-(3,7-Dimethylocta-2,6-dienylthio)-1H-imidazole (12)
This compound was prepared from 2-mercaptoimidazole
(0.12 g, 1.2 mmol) and geranyl chloride (0.19 ml, 1.0 mmol)
in 96% yield (0.227 g) by a similar procedure as for 9. The
crude product was pure by NMR and was utilized without further purification: Rf = 0.4 (50% EA/Hex); 1H δ 12.06 (br s,
1H), 7.17 (s, 1H), 5.29 (dt, 1H, J = 1.2, 7.6), 5.03 (m, 1H),
3.62 (d, 2H, J = 8), 2.05–1.92 (m, 4H), 1.65 (s, 3H), 1.56 (s,
3H), 1.46 (s, 3H); 13C δ 140.5, 139.6, 131.6, 123.9, 123.8,
119.0, 39.4, 33.4, 26.2, 25.6, 17.6, 15.6; IR 3094, 2916, 2637,
1447, 1328, 1098; HR-FABMS (3-NBA) calcd for C13H20N2S
(MH+): 237.1313; found 237.1310 (1.1 ppm).

5.3.7. (E)-5-(3,7-Dimethylocta-2,6-dienylthio)-1H-tetrazole
(9)
Into a solution of 5-mercapto-1H-tetrazole (0.20 g,
2.0 mmol) in ethyl alcohol (10 ml) were added K2CO3 (0.55 g,
4.0 mmol) and geranyl chloride (0.19 ml, 1.0 mmol). After
12 h, the reaction mixture was acidified to pH 7 and extracted
with 50% EA/Hex (3× 50 ml). The combined organic extracts
were dried with Na2SO4. The residue obtained upon concentration in vacuo was purified by flash chromatography (5:1:1
Hex/AcOH/EA) to furnish 0.213 g (89%) of mercaptotetrazole 9 as a colorless oil: Rf = 0.2 (5:1:1, Hex/AcOH/EA); 1H
δ 13.0 (br s, 1H), 5.37 (t, 1H, J = 7.6), 5.03 (t, 1H, J = 6.4),
3.97 (d, 2H, J = 8), 2.03 (m, 4H), 1.68 (s, 3H), 1.66 (s, 3H),
1.56 (s, 3H); 13C δ 155.1, 143.4, 132.1, 123.5, 116.8, 39.4,
31.4, 26.2, 26.6, 17.7, 16.2; IR 3055, 2917, 2727, 2560, 1504,
1447, 1038; HR-FABMS (3-NBA) calcd for C11H19N4 (MH+):
239.1330; found 239.1336 (2.2 ppm).
5.3.8. (E)-3-(3,7-Dimethylocta-2,6-dienylthio)-1H-1,2,4-triazole (10)
Into a solution of 1H-1,2,4-triazole-3-thiol (0.152 g,
1.50 mmol) in ethyl alcohol (10 ml) were added K2CO3
(0.276 g, 2.00 mmol) and geranyl chloride (0.19 ml,
1.0 mmol). After 12 h, the reaction mixture was worked up as
for 9 and the residue purified by flash chromatography (40%
EA/Hex) to furnish 0.235 g (99%) of thiotriazole 10: Rf = 0.3
(50% EA/Hex); 1H δ 13.70 (br s, 1H), 8.18 (s, 1H), 5.33 (dt,
1H, J = 1.2, 2), 5.02 (m, 1H), 3.80 (d, 2H, J = 8), 2.00 (m, 4H),
1.64 (s, 3H), 1.56 (s, 3H); 13C δ 156.4, 147.7, 141.5, 131.8,
131.8, 123.6, 118.1, 39.4, 31.2, 26.2, 25.6, 17.6, 16.0; IR 3111,
2924, 1449, 1276, 910, 734; MS (HR-FABMS, 3-NBA) calcd
for C12H20N3S, (MH+): 238.1378; found: 238.1383 (2.3 ppm).
5.3.9. (E)-4-(3,7-Dimethylocta-2,6-dienylthio)-1H-1,2,3-triazole (11)
Into a 0 °C solution of the sodium salt of 4-mercapto-1H1,2,3-triazole (0.262 g, 2.2 mmol) in ethanol (10 ml) was
added geranyl chloride (0.19 ml, 1.0 mmol). The reaction mixture was stirred for 2 h and then allowed to warm to RT over
the course of 1 h. The reaction mixture was diluted with water and the mixture extracted with 20% EA/Hex (3× 50 ml).
The combined organic extracts were dried with Na2SO4 and
concentrated, with the residue purified by flash chromatography (20% EA/Hex) to furnish 0.218 g (92%) of thiotriazole
11. Rf = 0.2 (20% EA/Hex); 1H δ 14.23 (br s, 1H), 7.72 (s,
1H), 5.28 (d of t, 1H, J = 1.2, 8), 5.02 (m, 1H), 3.54 (d, 2H,
J = 7.6), 1.97 (m, 4H), 1.64 (d, 3H, J = 0.8), 1.55 (s, 3H), 1.47
(s, 3H); 13C δ 140.7, 139.3, 133.5, 131.6, 123.7, 118.8, 39.3,
33.0, 26.2, 25.5, 17.6, 15.7; IR 3130, 2916, 1661, 1448, 1228,
1109, 839; HR-FABMS (3-NBA) calcd for C12H20N3S, MH+:
238.1378; found: 238.1369 (3.8 ppm).
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5.3.11. (E)-4-(4,8-Dimethylnona-3,7-dienyl)-1H-1,2,3-triazole (13)
Into a solution of (E)-6,10-dimethylundeca-5,9-dien-1yne37 (0.176 g, 1.00 mmol) in 9:1 DMF/MeOH (10 ml) was
added TMSN3 (1.3 ml, 10 mmol) followed by CuI (0.1 g,
0.5 mmol).21 The mixture was held at 100 °C for 12 h and
then allowed to cool to rt. The reaction mixture was diluted
with water and then extracted with 20% EA/Hex (3× 70 ml).
The combined organic layers were dried with Na2SO4 and
concentrated. The residue was purified by flash chromatography (20% EA/Hex) to furnish 0.168 g (77%) of triazole 13:
Rf = 0.2 (20% EA/Hex); 1H (CD3OD) δ 7.53 (s, 1H), 5.15 (dt,
1H, J = 1.2, 7.2), 5.05 (m, 1H), 2.76 (t, 2H, J = 7.6), 2.35 (q,
2H, J = 7.2), 2.04 (m, 2H), 1.98 (m, 2H), 1.65 (s, 3H), 1.57
(s, 3H), 1.54 (s, 3H); 13C (CD3OD, 100 MHz) δ 144.2, 137.7,
132.3, 128.7, 125.4, 124.2, 40.9, 28.8, 27.8, 26.1, 24.2, 17.9,
16.3; IR 3140, 2919, 2856, 1448, 1377, 1108, 983, 838; HRFABMS (3-NBA) calcd for C13H21N3 (MH+): 220.1814;
found: 220.1811 (1.1 ppm).
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